Rosetta Genomics said this week that the US Patent and Trademark Office has issued US Patent No. 7,943,745, covering the composition of matter for human hsa-miR-497 and its variants.
The patent is not yet listed in the USPTO database.
Rosetta said that human hsa-miR-497 is an "important component" of its miRview Mets and miRview Mets2 diagnostic tests, used to identify the tissue of origin in cancers of unknown primary.
Earlier this month, the company launched a US-based oncology sales team for these test (GSN 5/5/2011).
The new patent adds to 21 patents and more than 105 patent applications in the company's intellectual property portfolio.